Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an intravenous solution for intravenous use. It is indicated for the treatment of certain adult solid tumours, most notably non‑small cell lung cancer and breast cancer, where it acts to inhibit cell division.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company provides regulatory‑approved product batches to hospitals, pharmacies and procurement teams across the European Union and other global markets.

Vinorelbine is used in oncology for the management of solid tumours that respond to microtubule inhibition. - Non‑small cell lung cancer: improves disease control and overall survival as part of first‑line or second‑line chemotherapy regimens. - Breast cancer: used in combination protocols to reduce tumour burden and delay progression in metastatic or adjuvant settings. - Combination therapy for solid tumours: incorporated with other chemotherapeutic agents to enhance antitumour activity in approved regimens.

Vinorelbine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea: feeling of sickness often accompanied by vomiting. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Severe neutropenia with fever: can lead to life‑threatening infections. - Peripheral neuropathy: nerve damage causing numbness or tingling. - Pulmonary toxicity: inflammation or fibrosis of lung tissue.

When using Navirel, clinicians should observe several safety measures to minimise risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: evaluate hepatic enzymes before and during therapy as vinorelbine is metabolised hepatically. - Evaluate cardiac status: consider baseline ECG in patients with cardiac disease. - Avoid in active severe infection: postpone treatment if uncontrolled infection is present. - Use with caution in renal impairment: adjust dosing if renal function is compromised. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent myelosuppressive agents: combined use markedly increases risk of severe bone‑marrow suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise vinorelbine plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure and effectiveness. - Antiemetics containing serotonin antagonists: may alter nausea control and require dose adjustment. - Warfarin: vinorelbine may enhance anticoagulant effect, necessitating INR monitoring.